38 results
UPLOAD
IMCR
Immunocore Holdings plc
29 Jan 21
Letter from SEC
12:00am
. We note your comparison of the observed hazard ratio in your Phase 3
trial of tebentafusp
to the hazard ratios observed in several other Phase
6-K
EX-99.1
IMCR
Immunocore Holdings plc
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
and clinically meaningful overall survival (OS) benefit, hazard ratio of 0.51, with median OS of almost 22 months
(OXFORDSHIRE, England & CONSHOHOCKEN … , showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment. The OS Hazard Ratio (HR) in the intent-to-treat population
6-K
EX-99.1
IMCR
Immunocore Holdings plc
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
statistically and clinically meaningful overall survival (OS) benefit, hazard ratio of 0.51, with median OS of almost 22 months
(OXFORDSHIRE, England … undertaken in mUM, showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment. The OS Hazard Ratio (HR) in the intent-to-treat
CORRESP
IMCR
Immunocore Holdings plc
1 Feb 21
Correspondence with SEC
12:00am
of the observed hazard ratio in your Phase 3 trial of tebentafusp to the hazard ratios observed in several other Phase 3 trials of treatments for uveal
6-K
EX-99.1
IMCR
Immunocore Holdings plc
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
(OS) benefit, hazard ratio of 0.51, with median OS of almost 22 months
Company to host an investor call today at 8:30 AM ET
(OXFORDSHIRE, England … unprecedented median OS benefit as a first-line treatment. The OS Hazard Ratio (HR) in the intent-to-treat population favored KIMMTRAK, HR=0.51 (95
6-K
EX-99.3
otd91at9
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
CORRESP
a5ixd7u
15 Jan 21
Correspondence with SEC
12:00am
6-K
EX-99.2
6v806xzjgztf
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.1
9hevw9n1zpr0
24 Aug 21
Current report (foreign)
4:33pm
6-K
EX-99.1
bho5vbo1d
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
w5mshbh9g
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
q5ix sfas4mzyd
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
EX-99.3
kh15y6xa3cphze
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.1
xy0gy45omw iavzdef
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.2
3286fg
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.3
i6ddw 67s9ezhykfqd
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.3
ix5xi
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.4
ycih6d1c
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
kiihejo7rz 5rjf
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
9kb0 z5g9nvqky8iem5
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am